HONG KONG – Start-up antibody-focused Mabspace Biosciences Co. Ltd. has secured $15 million in series A financing with Lilly Asia Ventures to help move two of its cancer candidates into clinical studies and further its antibody pipeline.

HONG KONG – Celltrion Inc. had a seven-year partnership with Pfizer Inc.'s new subsidiary, Hospira Inc., to develop two biosimilar assets, but those ties were severed last week when Pfizer cut loose the rights for the two assets, saying that it plans to focus on a pipeline of in-house developed biosimilars.

HONG KONG – A move by a Chinese biotech conglomerate to build a biosimilars manufacturing facility could mark a step forward in the development of the market.

HONG KONG – A move by a Chinese biotech conglomerate to build a biosimilars manufacturing facility could mark a step forward in the development of the market.

HONG KONG – After being granted phase II trial approval in Sierra Leone last Saturday for its novel Ebola vaccine, Tianjin Cansino Biotechnology Inc. became the first Chinese vaccine company with a self-developed vaccine approved for clinical trials in a foreign country.

HONG KONG – Another China-based company has filed for a $100 million IPO on Nasdaq, testing what has been a friendly environment for biotech. Hutchison China Meditech Ltd. hasn't decided on the timeline of the listing, nor the number and price of shares. The proposed maximum offering price is $100 million.

HONG KONG – South Korean biotech Genexine Inc. licensed out three of its compounds for $100 million to a Chinese drug developer, exploring the Asian market for next-generation long-acting growth hormone treatments.